JP6604957B2 - ドネペジル組成物及びアルツハイマー病を治療する方法 - Google Patents

ドネペジル組成物及びアルツハイマー病を治療する方法 Download PDF

Info

Publication number
JP6604957B2
JP6604957B2 JP2016549781A JP2016549781A JP6604957B2 JP 6604957 B2 JP6604957 B2 JP 6604957B2 JP 2016549781 A JP2016549781 A JP 2016549781A JP 2016549781 A JP2016549781 A JP 2016549781A JP 6604957 B2 JP6604957 B2 JP 6604957B2
Authority
JP
Japan
Prior art keywords
donepezil
dosage form
capsule
memantine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506624A (ja
JP2017506624A5 (enExample
Inventor
マヘンドラ ジー デディヤ
カヴィータ ヴェルマーニ
アショク カダイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53753905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6604957(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2017506624A publication Critical patent/JP2017506624A/ja
Publication of JP2017506624A5 publication Critical patent/JP2017506624A5/ja
Application granted granted Critical
Publication of JP6604957B2 publication Critical patent/JP6604957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JP2016549781A 2014-02-04 2015-02-04 ドネペジル組成物及びアルツハイマー病を治療する方法 Active JP6604957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461935596P 2014-02-04 2014-02-04
US61/935,596 2014-02-04
PCT/US2015/014404 WO2015120013A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and method of treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019188336A Division JP2020037556A (ja) 2014-02-04 2019-10-15 ドネペジル組成物及びアルツハイマー病を治療する方法

Publications (3)

Publication Number Publication Date
JP2017506624A JP2017506624A (ja) 2017-03-09
JP2017506624A5 JP2017506624A5 (enExample) 2018-03-22
JP6604957B2 true JP6604957B2 (ja) 2019-11-13

Family

ID=53753905

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016549781A Active JP6604957B2 (ja) 2014-02-04 2015-02-04 ドネペジル組成物及びアルツハイマー病を治療する方法
JP2019188336A Pending JP2020037556A (ja) 2014-02-04 2019-10-15 ドネペジル組成物及びアルツハイマー病を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019188336A Pending JP2020037556A (ja) 2014-02-04 2019-10-15 ドネペジル組成物及びアルツハイマー病を治療する方法

Country Status (7)

Country Link
US (2) US20150216849A1 (enExample)
EP (1) EP3102186B1 (enExample)
JP (2) JP6604957B2 (enExample)
CA (2) CA3214846A1 (enExample)
IL (2) IL247092B (enExample)
MX (1) MX383665B (enExample)
WO (1) WO2015120013A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3214846A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and methods of treating alzheimer's disease
US20180042922A1 (en) * 2016-08-15 2018-02-15 Axovant Sciences Gmbh Compositions and methods of treating a neurodegenerative disease
US11197850B2 (en) * 2017-02-23 2021-12-14 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Powder injection of the donepezil semi palmoxiric acid salt, composition containing same and preparation method therefor
WO2020068731A1 (en) * 2018-09-25 2020-04-02 The General Hospital Corporation Methods for integrating cell gene expression data from multiple single-cell data sets and uses thereof
WO2020208398A1 (es) * 2019-04-09 2020-10-15 Laboratorios Bagó S.A. Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10966989B2 (en) * 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
WO2022270663A1 (ko) * 2021-06-23 2022-12-29 동아에스티 주식회사 도네페질, 실로스타졸 및 아리피프라졸을 포함하는 치매, 인지장애 또는 혈관성 우울증의 예방, 개선 또는 치료용 약학적 조성물
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
EP4456883A4 (en) * 2021-12-28 2025-04-16 ILKO Ilaç Sanayi ve Ticaret A.S. Donepezil-Memantine Extended-Release Capsule Composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
GEP20094759B (en) 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
JP2008517022A (ja) 2004-10-19 2008-05-22 クルカ， トバルナ ズドラビル， デー．デー．， ノボ メスト 塩酸ドネペジルを含有する固形薬学的組成物
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060160852A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
KR101213345B1 (ko) * 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 항치매약을 함유하는 조성물
EP1946780B1 (en) * 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
EP2211836A2 (en) 2007-10-10 2010-08-04 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
TWI491395B (zh) 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
CN102309465B (zh) * 2010-06-30 2015-04-22 天津药物研究院 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
US20140243278A1 (en) * 2011-07-05 2014-08-28 Sunil Sadanand Nadkarni Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
CA3214846A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and methods of treating alzheimer's disease

Also Published As

Publication number Publication date
CA3214846A1 (en) 2015-08-13
MX2016010179A (es) 2017-04-06
US20180169082A1 (en) 2018-06-21
JP2017506624A (ja) 2017-03-09
IL247092A0 (en) 2016-09-29
IL247092B (en) 2020-08-31
JP2020037556A (ja) 2020-03-12
EP3102186A1 (en) 2016-12-14
EP3102186A4 (en) 2017-06-28
US20150216849A1 (en) 2015-08-06
MX383665B (es) 2025-03-14
IL276315A (en) 2020-09-30
EP3102186B1 (en) 2021-01-27
WO2015120013A1 (en) 2015-08-13
CA2938671A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
JP6604957B2 (ja) ドネペジル組成物及びアルツハイマー病を治療する方法
JP7627302B2 (ja) パルボシクリブの固形剤形
CA2726472C (en) Solid pharmaceutical formulations comprising bibw 2992
JP6739470B2 (ja) デフェラシロクスの経口製剤
JP2009545557A (ja) 胃保持性のデリバリーシステム
KR20120059582A (ko) 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
Hadi et al. Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis.
KR102270521B1 (ko) 구토억제 서방형 고체 제형
US20140044780A1 (en) Extended-Release Levetiracetam and Method of Preparation
EP1128826A1 (en) Chromone enteric release formulation
CN106456611B (zh) 用于治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂
KR20040047920A (ko) 피페라진 우레아 유도체를 위한 고체 제약 제제
WO2015140709A1 (en) Solid pharmaceutical dosage forms
Kumar et al. Design and Evaluation of Gastroretentive Multiple Units of Dipyridamole: in-vitro and in-vivo human studies
Majekodunmi et al. Development of Extended-Release Formulation of Ibuprofen Using Blends of Calcium Silicate and Polyvinyl Pyrrolidone as Tablet Matrix
CN104582692A (zh) 包含抗生素和β-内酰胺酶抑制剂的组合物，其中抗生素和β-内酰胺酶抑制剂中的至少一种是迷你片剂的形式

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191015

R150 Certificate of patent or registration of utility model

Ref document number: 6604957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250